Who is sponsoring NCT04941885?

NCT04941885 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT04941885?

Interventions in NCT04941885: Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI.

What condition does NCT04941885 study?

NCT04941885 studies Breast Cancer.

Is NCT04941885 still recruiting?

NCT04941885 is currently status unknown. Last updated 2 July 2021.

Last reviewed 2021-07-02 · How we verify

NCT04941885: Increase

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer

Status unknown Phase 2 Last updated 2 July 2021

What this trial tests

Phase 2 trial testing Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI in Breast Cancer in 78 participants. Status unknown.

Timeline

25 June 2021

Primary endpoint
1 July 2023

1 July 2025

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	78
Start date	25 June 2021
Primary completion	1 July 2023
Estimated completion	1 July 2025
Sites	1 location across China

Drugs / interventions tested

Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the important mechanisms for suppressing tumors of Trastuzumab. Pre-clinical data suggest that the ADCC effect of Inetetamab, an anti-HER2 monoclonal antibody with a modified Fc segment, is 1.11 times that of trastuzumab. Previous studies indicated that enhanced ADCC effects can be transformed into clinical benefits. Immune induction through cyclophosphamide metronomic chemotherapy may further enhance the ADCC effect of anti-HER2 monoclonal antibodies. Therefore, we conducted this study to explore the efficacy and the safety of Inetetamab combined with cyclophosphamide metronomic chemotherapy and aromatase inhibitors(AI) in the treatment of metastatic HER2-positive and HR-positive breast cancer patients and to explore the possible mechanisms.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

HER2-targeted therapies in cancer: a systematic review.
Zhu K, Yang X, Tai H, Zhong X, et al · · 2024 · cited 83× · PMID 38308374 · DOI 10.1186/s40364-024-00565-1
Metronomic Chemotherapy in Elderly Patients.
Bandini A, Calabrò PF, Banchi M, Orlandi P, et al · · 2024 · cited 5× · PMID 38448722 · DOI 10.1007/s11912-024-01505-w
Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens.
Liu J, Mo H, Li Q, Cazzaniga ME, et al · · 2025 · PMID 41221152 · DOI 10.1002/cai2.70035
Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients.
Liang Y, Liu X, Yun Z, Li K, et al · · 2024 · PMID 38188468 · DOI 10.1177/17588359231220501

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04941885 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 2 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04941885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing